Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA.
加利福尼亞州南舊金山，2024年12月19日（環球新聞）-- Standard BioTools Inc.（納斯達克：LAB）今天宣佈，其總裁兼首席執行官邁克爾·埃霍姆博士將參加即將於1月13日至16日在加利福尼亞州舊金山的西方聖弗朗西斯酒店舉行的第43屆年度摩根大通醫療保健大會。
Dr. Egholm's corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT.
埃霍姆博士的公司演講將於2024年1月16日，上午9:45進行。
A live audio webcast will be available to investors and other interested parties by accessing the Investor Relations page of the Company's website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
投資者和其他感興趣的方可以通過訪問該公司網站的投資者關係頁面的活動與演講板塊來收聽直播音頻網絡播報。錄音將被存檔，並可在Standard BioTools投資者關係頁面（investors.standardbio.com）上獲取。
About Standard BioTools Inc.
關於Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook, LinkedIn, and YouTube.
標準生物工具公司（納斯達克：LAB），是SomaLogic公司的母公司，之前稱爲Fluidigm公司，擁有一系列成熟的、標準化的下一代技術，幫助生物醫藥研究人員更快、更好地開發藥物。作爲領先的解決方案提供商，該公司利用其自主研發的SomaScan、質量細胞術和微流體技術，在健康與疾病領域提供可靠且可重複的洞察，幫助將科學發現轉化爲更好的患者結果。標準生物工具與全球領先的學術、政府、藥品、生物技術、植物與動物研究及臨牀實驗室合作，專注於轉化和臨牀研究中最緊迫的需求，包括腫瘤學、免疫學和免疫治療。了解更多請訪問standardbio.com，或者在X、Facebook、LinkedIn和YouTube上與我們聯繫。
For Research Use Only. Not for use in diagnostic procedures.
僅供研究使用。不用於診斷程序。
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. 2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
有限使用標籤許可和其他條款可能適用：standardbio.com/legal/salesterms。
專利和許可信息：standardbio.com/legal/notices。
商標：standardbio.com/legal/trademarks。其他商標爲其各自所有者的獨有財產。2024標準生物工具公司（原Fluidigm公司）。版權所有。
Investor Contact
投資者聯繫
David Holmes
Gilmartin Group LLC
ir@standardbio.com
大衛·霍姆斯
吉爾馬丁集團有限責任公司
ir@standardbio.com
